In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adaptive Licensing: Industry On Board, With Caveats

Executive Summary

The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.

Advertisement

Related Content

EMA Ready To End Adaptive Pathways Pilot, Tap Into Lessons Learned
'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context
EMA Head On Transparency, Affordable Innovation, And What Patients Really Need
Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes
Rivalry Intensifies In Europe For Biotech Funding, Product Development
The UK’s Early Access Scheme: Breakthrough Or Mixed Blessing?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel